Bioline Rx reported $2.5M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Arca Biopharma USD 49.52M 2.58M Mar/2026
Bio Path 13.65M 3.37M Sep/2022
Bioline Rx USD 2.5M 5.41M Mar/2026
Capricor Therapeutics USD 105.42M 182.42M Mar/2026